Omics! Omics!

A computational biologist's personal views on new technologies & publications on genomics & proteomics and their impact on drug discovery

Tuesday, February 21, 2023

Is Illumina Delivering the MVP of Long Reads?

›
At AGBT last week Illumina released additional details on their still incubating Complete Long Reads (CLR) product (formerly known as Infini...
1 comment:
Sunday, February 05, 2023

What's AGBT Like?

›
AGBT begins in less than 24 hours, and the signs are everywhere here at the Diplomat Resort in Hollywood Florida.  I arrived Friday with fam...
2 comments:
Tuesday, January 31, 2023

AGBT 2023 Is Nearly Upon Us!

›
AGBT is less than a week away in Hollywood Florida - and I've been letting everything else get ahead of writing anything here.  The JP M...
1 comment:
Tuesday, October 25, 2022

PacBio Revio: Same Footprint, 80% The Time, 15X The HiFi!

›
PacBio has been rolling out announcements around the ASHG meeting and now delivers a huge one: the next generation SMRT instrument “Revio” w...
5 comments:
Wednesday, October 19, 2022

Better Than FizzBuzz: First Bioinformatics Problem in an Erratic Series of Indeterminant Length

›
Periodically in my work or during writing this blog I come across computational problems that have the aspects of making, at least in my min...
2 comments:
Thursday, October 06, 2022

General Inception Aims to Ignite New Company Formation

›
A week ago, a company calling itself General Inception emerged from stealth as a new concept, which they call an “Igniter company”, to promo...
2 comments:
Wednesday, October 05, 2022

What Conversation Does Each Sequencing Instrument Vendor Wish You To Have?

›
6 comments:
Monday, October 03, 2022

Illumina Roadmap Part 2: Infinity Becomes Illumina Complete Long Reads

›
The Only Thing Clear About Infinity Is It Is Now Complete Long Reads.  Illumina told us a new name for Infinity -- Illumina Complete Long Re...
4 comments:
Sunday, October 02, 2022

Illumina Roadmap Part 1: NovaSeq Xplus & XLEAP-SBS Chemistry

›
4 comments:
Wednesday, September 21, 2022

Notes From Coffee With MGI

›
A couple of weeks ago  I sat down for coffee with a pair of MGI representatives - American Region CEO Yongwei Zhang and Director, Global Bus...
2 comments:
Tuesday, August 23, 2022

SRA Entries Should Not Ever Disappear Into Thin Air

›
I ran into an annoying problem last night and was quite steamed, but had the discipline to wait until morning to vent publicly about it.  No...
2 comments:
Tuesday, August 16, 2022

Supply Stall Slows Singular

›
Singular Genomics reported earnings last week and delivered an unpleasant surprise: inability of suppliers to make timely deliveries of key ...
3 comments:
Thursday, June 23, 2022

AGBT 2022: Overhanging Questions

›
AGBT broke up a couple of weeks ago and I've failed to write anything here so far.  It was frustrating not attending, but not registerin...
6 comments:
Wednesday, June 08, 2022

Admin: Feedburner to Follow.it Switch

›
A bit over a year ago Google made one of their dreaded announcements that they would be slowly killing off one of their acquisitions, in thi...
Tuesday, May 31, 2022

Ultima Genomics Storms Out Of Stealth Promising $1/Gigabase Short Reads

›
To date, the new entrants targeting Illumina’s short read business have been aiming at the middle of Illumina’s range, trying to take on Nex...
7 comments:
Monday, May 23, 2022

London Calling 2022: Peptide Sequencing

›
London Calling was last week and Clive Brown's big revelation was a peek at Oxford Nanopore's progress on enabling peptide sequencin...
Friday, April 15, 2022

Nanopore Knights' Notes

›
Clive Brown gave a "mezzanine" update on Oxford Nanopore just over two weeks ago titled "The Knights Who Say Me".  Clive...
2 comments:
Thursday, March 31, 2022

The End of the Beginning of Human Genome Sequencing?

›
Today in Science  a slew of papers have been published from the Telomere-to-Telomere (T2T) Consortium.  The flagship paper details the gener...
2 comments:
Monday, March 14, 2022

Element Unveils AVITI

›
Element Biosciences is launching their AVITI sequencing system today in a blitz of events.  At February’s end they flew me out to visit thei...
4 comments:
Thursday, February 17, 2022

Pro Tip: Customer Hostile is Never A Good Look

›
A bizarre incident happened on Twitter yesterday.  Someone contemplating using Oxford Nanopore to sequence a large, complex genome on a tigh...
8 comments:
‹
›
Home
View web version

About Me

My photo
Keith Robison
Dr. Robison spent 10 years at Millennium Pharmaceuticals working with various genomics & proteomics technologies & working on multiple teams attempting to apply these throughout the drug discovery process. He spent 2 years at Codon Devices working on a variety of protein & metabolic engineering projects as well as monitoring a high-throughput gene synthesis facility. After a brief bit of consulting, he rejoined the cancer drug discovery field at Infinity Pharmaceuticals in May 2009. In September 2011 he joined Warp Drive Bio, a startup applying genomics to natural product drug discovery. In February 2019 he joined Ginkgo Bioworks, a synthetic biology company. Other recurring characters in this blog are his late loyal Shih Tzu Amanda, his current Shih Poo Lily and his now adult son alias TNG (The Next Generation). Dr. Robison can be reached via his Gmail account, keith.e.robison@gmail.com You can also follow him on Twitter as @OmicsOmicsBlog.
View my complete profile
Powered by Blogger.